Matches in SemOpenAlex for { <https://semopenalex.org/work/W3016540505> ?p ?o ?g. }
Showing items 1 to 81 of
81
with 100 items per page.
- W3016540505 endingPage "429" @default.
- W3016540505 startingPage "425" @default.
- W3016540505 abstract "To date, there has been no study that compares the efficacy and safety of warfarin in atrial fibrillation (AF) patients with Evaluated Heartvalves, Rheumatic or Artificial (EHRA) type 2 valvular heart disease (VHD). This study was conducted to determine the optimal INR in these patients.This retrospective study enrolled AF patients with EHRA type 2 VHD receiving warfarin in Central Chest Institute of Thailand between January 2016 and December 2018. The incidence density of thromboembolic or bleeding events was calculated. The International normalized ratio (INR) was classified into six groups (less than 1.50, 1.50 to 1.99, 2.00 to 2.49, 2.50 to 2.99, 3.00 to 3.49, and 3.50 or more). The optimal INR level was defined as the lowest incidence density of thromboembolic events and bleeding complications.A total of 200 AF patients with EHRA type 2 VHD receiving warfarin were enrolled, contributing to 289 patient-years of observation period. There were 13 thromboembolic events (4.5 per 100 patient-years) and 16 bleeding events (5.5 per 100 patient-years). The incidence density of thromboembolic events was significantly increased in the INR level below 2.00 (P = .03), while the INR level of 3.50 or more was significantly increased in the incidence density of major bleeding events (P = .03). Total bleeding and minor bleeding were increased significantly in INR level of 2.50 or more (P = .04).The INR of 2.00 to 2.49 was appeared to be associated with the lowest incidence density of thromboembolic and bleeding events in these patients." @default.
- W3016540505 created "2020-04-24" @default.
- W3016540505 creator A5059561732 @default.
- W3016540505 creator A5079723050 @default.
- W3016540505 creator A5088998636 @default.
- W3016540505 date "2020-04-15" @default.
- W3016540505 modified "2023-09-27" @default.
- W3016540505 title "Optimal INR level in patients with atrial fibrillation with EHRA type 2 valvular heart disease receiving warfarin" @default.
- W3016540505 cites W164627193 @default.
- W3016540505 cites W2073423663 @default.
- W3016540505 cites W2081205482 @default.
- W3016540505 cites W2087484885 @default.
- W3016540505 cites W2096246254 @default.
- W3016540505 cites W2097854437 @default.
- W3016540505 cites W2122779695 @default.
- W3016540505 cites W2136489990 @default.
- W3016540505 cites W2162508946 @default.
- W3016540505 cites W2170421103 @default.
- W3016540505 cites W2340635798 @default.
- W3016540505 cites W2737130990 @default.
- W3016540505 cites W2792857103 @default.
- W3016540505 cites W323873945 @default.
- W3016540505 cites W4211129082 @default.
- W3016540505 doi "https://doi.org/10.1002/joa3.12342" @default.
- W3016540505 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7279990" @default.
- W3016540505 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32528567" @default.
- W3016540505 hasPublicationYear "2020" @default.
- W3016540505 type Work @default.
- W3016540505 sameAs 3016540505 @default.
- W3016540505 citedByCount "2" @default.
- W3016540505 countsByYear W30165405052022 @default.
- W3016540505 countsByYear W30165405052023 @default.
- W3016540505 crossrefType "journal-article" @default.
- W3016540505 hasAuthorship W3016540505A5059561732 @default.
- W3016540505 hasAuthorship W3016540505A5079723050 @default.
- W3016540505 hasAuthorship W3016540505A5088998636 @default.
- W3016540505 hasBestOaLocation W30165405051 @default.
- W3016540505 hasConcept C120665830 @default.
- W3016540505 hasConcept C121332964 @default.
- W3016540505 hasConcept C126322002 @default.
- W3016540505 hasConcept C164705383 @default.
- W3016540505 hasConcept C2776301958 @default.
- W3016540505 hasConcept C2779161974 @default.
- W3016540505 hasConcept C2779736815 @default.
- W3016540505 hasConcept C2781362458 @default.
- W3016540505 hasConcept C61511704 @default.
- W3016540505 hasConcept C71924100 @default.
- W3016540505 hasConceptScore W3016540505C120665830 @default.
- W3016540505 hasConceptScore W3016540505C121332964 @default.
- W3016540505 hasConceptScore W3016540505C126322002 @default.
- W3016540505 hasConceptScore W3016540505C164705383 @default.
- W3016540505 hasConceptScore W3016540505C2776301958 @default.
- W3016540505 hasConceptScore W3016540505C2779161974 @default.
- W3016540505 hasConceptScore W3016540505C2779736815 @default.
- W3016540505 hasConceptScore W3016540505C2781362458 @default.
- W3016540505 hasConceptScore W3016540505C61511704 @default.
- W3016540505 hasConceptScore W3016540505C71924100 @default.
- W3016540505 hasIssue "3" @default.
- W3016540505 hasLocation W30165405051 @default.
- W3016540505 hasLocation W30165405052 @default.
- W3016540505 hasLocation W30165405053 @default.
- W3016540505 hasLocation W30165405054 @default.
- W3016540505 hasOpenAccess W3016540505 @default.
- W3016540505 hasPrimaryLocation W30165405051 @default.
- W3016540505 hasRelatedWork W2048824205 @default.
- W3016540505 hasRelatedWork W2053292521 @default.
- W3016540505 hasRelatedWork W2063589187 @default.
- W3016540505 hasRelatedWork W2323255267 @default.
- W3016540505 hasRelatedWork W2350497074 @default.
- W3016540505 hasRelatedWork W2353553663 @default.
- W3016540505 hasRelatedWork W2490787293 @default.
- W3016540505 hasRelatedWork W2804271639 @default.
- W3016540505 hasRelatedWork W2919475727 @default.
- W3016540505 hasRelatedWork W3041109162 @default.
- W3016540505 hasVolume "36" @default.
- W3016540505 isParatext "false" @default.
- W3016540505 isRetracted "false" @default.
- W3016540505 magId "3016540505" @default.
- W3016540505 workType "article" @default.